Disitamab vedotin plus radiation for high-risk bladder cancer in kidney tube
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had surgery to remove a kidney and ureter for cancer in the upper urinary tract
- Your cancer stage after surgery is pT3-pT4N0M0 or had spread to lymph nodes (pTxN+)
- Your cancer cells tested as 1+, 2+, or 3+ for a protein called HER2
- You cannot take cisplatin chemo because of poor kidney function, hearing loss, nerve damage, heart failure, or being frail (ECOG 2)
- You have not had other cancer treatments before this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) to treat HER2-positive high-risk upper tract urothelial cancer, aiming to save the kidney instead of removing it. The drugs target cancer cells and boost the immune system to fight the cancer.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
This study tests whether a combination of two drugs can treat bladder cancer without needing to remove the bladder. It is for people whose cancer has not spread beyond the bladder and who prefer to avoid surgery.
This trial tests a targeted therapy (disitamab vedotin, also called RC48) given directly into the bladder after surgery for HER2-positive upper tract urothelial cancer. The goal is to see if it helps prevent the cancer from coming back.
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.